Cancer incidence in multiple sclerosis: A 35-year follow-up

Neuroepidemiology

Volumn 23, Issue 5, 2004, Pages 224-227

  Sumelahti, Marja Liisa ^a   Pukkala, Ero ^b   Hakama, Matti ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

Author keywords

Aetiology; Cancer risk; Multiple sclerosis

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; FEMALE; FINLAND; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS;

ADULT; ENVIRONMENTAL EXPOSURE; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEOPLASMS; RISK FACTORS; TIME FACTORS;

EID: 4444334818     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079947     Document Type: Article

References (28)

1. Lassmann H: Mechanisms of demyelination and tissue destruction in multiple sclerosis. Clin Neurol Neurosurg 2002;104:168-171.
2. Sumelahti ML,Tienari PJ, Wikström J, Palo J, Hakama M: Regional and temporal variation in the incidence of multiple sclerosis in Finland 1979-1993. Neuroepidemiology 2000;19:67-75.
3. Sadovnick AD, Ebers GC, Wilson RW, Paty DW: Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-994.
4. Koch-Henriksen N, Bronnum-Hansen H, Stenager E: Underlying cause of death in Danish patients with multiple sclerosis: Results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-59.
5. Sumelahti ML, Tienari PJ, Wikström J, Salminen TMJ, Hakama M: Survival of multiple sclerosis in Finland between 1964 and 1993. Mult Scler 2002;8:5-10.
6. Palo J, Duchesne J, Wikström J: Malignant diseases among patients with multiple sclerosis. J Neurol 1977;216:217-222.
7. Moller H, Kneller R, Boice JD, Olsen J: Cancer incidence following hospitalisation for multiple sclerosis in Denmark. Acta Neurol Scand 1991;84:214-220.
8. Amato MP, Pracucci G, Ponziani G, Siracusa G, Fratiglioni L, Amaducci L: Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 1993;43:831-833.
9. Midgard R, Glattre E, Gronning M, Riise T, Edland A, Nyland H: Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand 1996;93:411-415.
10. Wynn DR, Rodriquez M, O'Fallon WM, Kurland LT: A reappraisal of the epidemiology of multiple sclerosis in Olmstead County, Minnesota. Neurology 1990;40:780-786.
11. Compston A: Genetic epidemiology of multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62:553-561.
12. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon, IARCPress, 2001.
13. Poser CM, Paty DW, Scheinberg L, McDonald WI, et al: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231.
14. Pukkala E: Use of record linkage in small-area studies; in Elliot P, Guzic J, English D, Stern R (eds): Geographical and Environmental Epidemiology. Oxford, Oxford University Press, 1992, pp 125-131.
15. dos Santos Silva I: Cancer Epidemiology: Principles and Methods. Lyon, International Agency for Research on Cancer, WHO, 1999, pp 71-74.
16. Weinshenker BG: Epidemiological strategies to detect an exogenous cause of MS. Acta Neurol Scand Suppl 1995;161:93-99.
17. Hibberd PL: Use and misuse of statistics for epidemiological studies of multiple sclerosis. Ann Neurol 1994;36:218-230.
18. Keskimäki I, Aro S: Accuracy of data data on diagnosis, procedures and accidents in the Finnish hospital discharge register. Int J Health Sci 1991;2:15-21.
19. Braun DK, Dominguez G, Pellett PE: Human herpesvirus 6. Clin Microbiol Rev 1997;10:521-567.
20. Wrensch M, Weinberg A, Wiencke J, Miike R, Barger G, Kelsey K: Prevalence of antibodies to four herpesviruses among adults with glioma and controls. Am J Epidemiol 2001;154:161-165.
21. Ascherio A, Munger A, Lennette E, Spiegelman D, Hernan M, Olek M, Hankinson S, Hunter D: Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study. JAMA 2001;286:3083-3088.
22. Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A: Multiple sclerosis and Epstein-Barr virus. JAMA 2003;283:1533-1536.
23. Herrmann K, Niedobitek G: Epstein-Barr virus-associated carcinomas: Facts and fiction. J Pathol 2003:199;140-145.
24. Grufferman S, Delzell E: Epidemiology of Hodgkin's disease. Epidemiol Rev 1984;6:76-106.
25. Kurtzke JF, Auth TL, Beebe GW, Kurland LT, et al: Survival in multiple sclerosis. Trans Am Neurol Assoc 1969;94:134-139.
26. Ebers GC, Sadovnick AD, Risch NJ: A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995;377:150-151.
27. Vial T, Descotes J: Immunosuppressive drugs and cancer. Toxicology 2003;185:229-240.
28. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G: Risk of cancer from azathioprine therapy in multiple sclerosis. Neurology 1996;46:1607-1612.